0001437749-22-024809.txt : 20221026
0001437749-22-024809.hdr.sgml : 20221026
20221026170023
ACCESSION NUMBER: 0001437749-22-024809
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221024
FILED AS OF DATE: 20221026
DATE AS OF CHANGE: 20221026
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ESHELMAN FREDRIC N
CENTRAL INDEX KEY: 0001033409
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36361
FILM NUMBER: 221333917
MAIL ADDRESS:
STREET 1: PPD INC
STREET 2: 929 NORTH FRONT STREET
CITY: WILMINGTON
STATE: NC
ZIP: 28401
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eshelman Ventures, LLC
CENTRAL INDEX KEY: 0001706673
STATE OF INCORPORATION: NC
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36361
FILM NUMBER: 221333916
BUSINESS ADDRESS:
STREET 1: 319 N. 3RD STREET, SUITE 301
CITY: WILMINGTON
STATE: NC
ZIP: 28401
BUSINESS PHONE: 910 558 6885
MAIL ADDRESS:
STREET 1: 319 N. 3RD STREET, SUITE 301
CITY: WILMINGTON
STATE: NC
ZIP: 28401
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aravive, Inc.
CENTRAL INDEX KEY: 0001513818
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 264106690
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: RIVER OAKS TOWER
STREET 2: 3730 KIRBY DRIVE, SUITE 1200
CITY: HOUSTON
STATE: TX
ZIP: 77098
BUSINESS PHONE: 936-355-1910
MAIL ADDRESS:
STREET 1: RIVER OAKS TOWER
STREET 2: 3730 KIRBY DRIVE, SUITE 1200
CITY: HOUSTON
STATE: TX
ZIP: 77098
FORMER COMPANY:
FORMER CONFORMED NAME: Versartis, Inc.
DATE OF NAME CHANGE: 20110223
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-10-24
0001513818
Aravive, Inc.
ARAV
0001033409
ESHELMAN FREDRIC N
C/O ARAVIVE, INC., RIVER OAKS TOWER,
3730 KIRBY DRIVE, SUITE 1200
HOUSTON
TX
77098
1
1
1
Executive Chairman
0001706673
Eshelman Ventures, LLC
C/O ARAVIVE, INC., RIVER OAKS TOWER,
3730 KIRBY DRIVE, SUITE 1200
HOUSTON
TX
77098
1
1
Common Stock
2022-10-24
4
A
0
16306120
0.9199
A
25517889
I
See footnote
Series A Warrants (right to buy)
0.7949
2022-10-24
4
A
0
8153060
A
Common stock
8153060
8153060
I
See footnote
Series B Warrants (right to buy)
0.7949
2022-10-24
4
A
0
8153060
A
Common stock
8153060
8153060
I
See Footnote
On October 24, 2022, Aravive, Inc. (the "Company") agreed to issue approximately $41.5 million of securities including shares of its common stock and warrants (the "Warrants") to purchase shares of common stock in a private placement transaction (the "Private Placement") to certain investors, including Eshelman Ventures, LLC. The combined purchase price of each share of common stock and accompanying Warrants is $0.9199.
The shares of common stock and Warrants reported herein are owned directly by Eshelman Ventures, LLC, an entity wholly owned by the reporting person, Dr. Fredric N. Eshelman. Dr. Eshelman is the Executive Chairman of the Company's Board of Directors and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
The Series A Warrants are exercisable at any time after the Authorized Share Increase (as defined below) and will expire on the date that is the later of (i) fifteen (15) months after the date of the Authorized Share Increase, or (ii) one (1) month after public announcement by or on behalf of the Company of the publication of top line data from the Company's Phase 3 trial of batiraxcept in platinum-resistant ovarian cancer.
In connection with the Private Placement, the Company has agreed to convene a special meeting of its stockholders or to seek written consent of the stockholders no later than 120 days following the closing of the Private Placement to seek approval of an increase in the number of the Company's authorized shares of common stock pursuant to an amendment to the Company's Certificate of Incorporation (such increase, the "Authorized Share Increase") to allow for full sufficient authorized and unissued shares of common stock for the full exercise of all of the Warrants and the shares of common stock issuable upon exercise thereof.
The Series B Warrants are exercisable at any time after the Authorized Share Increase and will expire thirty (30) months after the Authorized Share Increase.
/s/ ESHELMAN VENTURES, LLC, By: Fredric N. Eshelman, Name: Fredric N. Eshelman, Title: Managing Member
2022-10-26
/s/ Fredric N. Eshelman
2022-10-26